GlassScriptPhysician profile
Brian C Ruley
NPI 1386758639
$11,071.32
in general payments reported to CMS, 2019-2025
65 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $1,937 · 2021: $2,138 · 2022: $1,681 · 2023: $1,496 · 2024: $1,008 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,850 · Education: $35.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.75 |
| Education | $35.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,637.65 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,109.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $749.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $666.31 | 2019-2025 | |
| Amarin Pharma, INC. | $570.87 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.67 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $518.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $502.86 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $344.52 | 2023-2025 | Rexulti |
| Bausch Health US, LLC | $334.92 | 2019-2022 | |
| Amgen INC. | $294.17 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Allergan, INC. | $287.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.43 | 2019-2023 | Gattex, Trintellix |
| Merck Sharp & Dohme LLC | $226.64 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.56 | 2022-2025 | Caplyta |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ruley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.